3B BlackBio Dx Ltd (3BBLACKBIO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by 3B BlackBio Dx Ltd on NSE and BSE, with an AI summary of each filing.
Re-appointment of director who retires by rotation and being eligible, offers for re-appointment
Change in Management · 30 Sept 2026, 10:31 pm
3B BlackBio Dx Shareholders Approve Re-Appointment of Director Mithla Dubey At the 54th Annual General Meeting held on 29th Sep'26, shareholders of 3B BlackBio Dx Limited approved the re-appointment of promoter director Mrs. Mithla Dubey (79), who retired by rotation and offered herself for re-appointment. Mrs. Dubey serves as a woman director on the board and is the mother of Chairman & Managing Director Dhirendra Dubey and Whole-Time Director & CFO Nikhil Kuber Dubey. The company confirmed she is not debarred from holding directorial office under any SEBI or regulatory order.
Scrutinizer''s Report and Voting report for 54th AGM
Annual General Meeting · 30 Sept 2026, 10:12 pm
Outcome of AGM
Annual General Meeting · 29 Sept 2026, 8:56 pm
Analyst/Investor Meet- Outcome
Others · 16 Sept 2026, 5:57 pm
3B BlackBio Dx Concludes Investor Interaction with Marcellus Investment Managers 3B BlackBio Dx Limited concluded a one-on-one investor meeting with Marcellus Investment Managers on 16th Sep'26. The company reiterated publicly available disclosures from its Q1-FY27 investor presentation, earlier filed on 13th Aug'26 following the financial results for the quarter ended 30th Jun'26. No unpublished price-sensitive information was shared during the interaction.
Analyst/Investor Meet intimation
Intimation · 11 Sept 2026, 7:46 pm
3B BlackBio Dx Schedules Investor Interaction with Marcellus Investment Managers 3B BlackBio Dx Ltd. (formerly Kilpest India Limited) has scheduled a virtual, one-on-one investor conference call with Marcellus Investment Managers, Mumbai, on 16th Sep'26 at 11:00 hrs IST. The company confirmed that discussions will rely strictly on publicly available information, specifically utilizing the Q1-FY27 investor presentation previously submitted to exchanges on 13th Aug'26. No unpublished price-sensitive information will be shared during the meeting.
Analyst/ Investor Meet Outcome
Others · 11 Sept 2026, 6:04 pm
3B BlackBio Dx Concludes One-on-One Investor Meeting with Capri Global Holdings 3B BlackBio Dx Limited conducted a one-on-one investor meeting with Capri Global Holdings, Mumbai, on 11th Sep'26. The company discussed publicly available information, reiterating details from its Q1-FY27 investor presentation previously submitted to exchanges on 13th Aug'26. Management confirmed that no unpublished price sensitive information was shared during the interaction.
Letter to Shareholders
Others (Uncategorized) · 07 Sept 2026, 9:18 pm
3B BlackBio Dx Schedules 54th AGM and E-Voting Details 3B BlackBio Dx Limited (formerly Kilpest India Limited) announced its 54th Annual General Meeting (AGM) will be held on 29th Sep'26 at 11:30 AM IST via Video Conferencing/OAVM. In compliance with SEBI LODR regulations, the FY26 Annual Report and AGM Notice have been dispatched to unregistered shareholders via weblink. The cut-off date for e-voting eligibility is 22nd Sep'26. The remote e-voting window opens on 26th Sep'26 at 9:00 AM IST and concludes on 28th Sep'26 at 5:00 PM IST.
Annual General Meeting to be held on 29th September, 2026
Annual General Meeting · 07 Sept 2026, 8:13 pm
Dividend updates
Annual General Meeting · 07 Sept 2026, 8:05 pm
3B BlackBio Dx Schedules 54th AGM, Dividend Record Date, and E-Voting 3B BlackBio Dx Limited announced its 54th AGM is scheduled for 29th Sep'26 via VC/OAVM. The company fixed the record date as 22nd Sep'26 for determining shareholder eligibility for FY26 dividend and remote e-voting. Book closure is set from 23rd Sep'26 to 29th Sep'26 (both days inclusive). Remote e-voting runs from 26th Sep'26 (9:00 AM IST) to 28th Sep'26 (5:00 PM IST). Subject to shareholder approval, the FY26 dividend will be paid on or after 5th Oct'26.
Record date and date of book closure for the purpose of Dividend and AGM
Annual General Meeting · 07 Sept 2026, 7:59 pm
Reg 34 (1) Annual Report FY 2025-26
Others (Uncategorized) · 07 Sept 2026, 7:27 pm
Notice of Annual General Meeting to be held on 29th September, 2026
Annual General Meeting · 07 Sept 2026, 7:07 pm
Analyst/Investor Meet Intimation
Intimation · 05 Sept 2026, 9:10 pm
3B BlackBio Dx Schedules One-on-One Investor Call with Capri Global Holdings 3B BlackBio Dx Limited (formerly Kilpest India Limited) announced a one-on-one virtual investor conference call scheduled for 11th Sep'26 at 11:00 AM IST with Capri Global Holdings, Mumbai. The company confirmed that discussions will rely on its previously filed Q1-FY27 investor presentation dated 13th Aug'26. Only public domain information will be shared, with no unpublished price-sensitive information discussed during the interaction.
Analyst/Investor Meet Outcome
Others · 29 Aug 2026, 8:25 pm
3B BlackBio Dx Ltd. Investor Meeting Outcome 3B BlackBio Dx Ltd. held a one-on-one meeting with Param Capital on 29th Aug'26. The company confirmed that only publicly available information was discussed, with no unpublished price-sensitive information being shared. During the meeting, management reiterated the contents of its Q1-FY27 investor presentation, which was previously submitted to exchanges on 13th Aug'26 following the results for the quarter ended 30th Jun'26. A link to the presentation was provided for reference.
Analyst/ Investor Meet Intimation
Intimation · 25 Aug 2026, 11:04 pm
3B BlackBio Dx Schedules One-on-One Investor Meeting 3B BlackBio Dx Ltd. has scheduled a one-on-one virtual investor conference call with Param Capital, Mumbai on 29th Aug'26 at 13:00 hrs IST. The company will use its Q1-FY27 investor presentation for the discussion. Management confirmed that no unpublished price-sensitive information will be shared during the meeting. The meeting details are subject to change.
Investor''s Presentation
Investor Presentation · 13 Aug 2026, 9:59 pm
3B BlackBio Dx: Q1FY27 Results Impacted by Coris Acquisition For Q1FY27, consolidated revenue grew 50.6% YoY to ₹3,349.08 Lakh, driven by the inclusion of Coris sales (₹862.83 Lakh), which were not in Q1FY26 figures. However, Profit After Tax declined 29.0% YoY to ₹897.84 Lakh, pressured by Coris' negative EBITDA of ₹(352.24) Lakh. Excluding Coris, core business revenue rose 11.8% YoY to ₹2,486.24 Lakh, with PAT up 8.2% to ₹1,367.66 Lakh. The company projects 15-20% overall growth for FY27, targeting international expansion and new product launches to drive future performance.
Unaudited Financial Results for the quarter ended 30th June, 2026
Financial Result · 13 Aug 2026, 9:45 pm
3B BlackBio Dx Q1 FY27: Strong Standalone PAT Growth, Consolidated PAT Declines 3B BlackBio Dx reported Q1 FY27 standalone net profit of ₹14.11 Cr, up 13.3% YoY but down 55.4% QoQ. Standalone revenue grew 12.7% YoY to ₹22.95 Cr. On a consolidated basis, Q1 FY27 net profit fell 29.0% YoY to ₹8.98 Cr, while revenue rose 49.7% YoY to ₹33.49 Cr. The Diagnostic kits segment drove 95.7% of consolidated revenue, showing 60.6% YoY growth. The board also approved the appointment of M/s Sanjay Kasliwal & Associates as Cost Auditor for FY27.
Outcome of Board Meeting held on 13th August, 2026
Outcome · 13 Aug 2026, 9:38 pm
3B BlackBio Dx Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 3,349 (+50.6% YoY | -5.5% QoQ) ■ EBITDA: 852 (-28.0% YoY | +0.4% QoQ) ■ EBITDA Margin (%): 25.4 (-2778 bps YoY | +148 bps QoQ) ■ PAT: 953 (-24.3% YoY | -0.2% QoQ) ■ EPS (INR): 10.5 (-29.0% YoY | -8.4% QoQ) 3B BlackBio Dx Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) Segmental Performance Agrochemicals ■ Revenue: 143 (-37.0% YoY | -57.6% QoQ) ■ EBIT: 0.0 (Loss to Profit YoY | -99.7% QoQ) ■ EBIT Margin (%): 0.0 (Loss to Profit YoY | -322 bps QoQ) Diagnostic kits ■ Revenue: 3,206 (+60.6% YoY | +0.0% QoQ) ■ EBIT: 1,332 (-16.3% YoY | -9.0% QoQ) ■ EBIT Margin (%): 41.6 (-3819 bps YoY | -412 bps QoQ)
3B Blackbio Dx Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve the Unaudited Standalone and ....
Intimation · 13 Aug 2026, 5:30 am
3B BlackBio Dx Board to Approve Q1 FY27 Results on 13th Aug'26 3B BlackBio Dx Ltd. has scheduled a Board of Directors meeting on 13th Aug'26 to consider and approve the unaudited standalone and consolidated financial results for the first quarter ended 30th Jun'26. In connection with this, the trading window for designated persons, which closed on 1st Jul'26, will reopen 48 hours after the results are announced.
Intimation to the holders of physical securities to furnish KYC details
Others (Uncategorized) · 09 Jul 2026, 9:59 pm
3B BlackBio Dx Reminds Physical Shareholders to Update KYC Details 3B BlackBio Dx Ltd., on 09 Jul'26, notified the BSE of its communication urging holders of physical securities to furnish mandatory KYC details. This includes PAN, bank account, and contact information. The company highlighted that as per SEBI regulations effective 01 Apr'24, physical shareholders with outdated KYC details (excluding nomination) are only eligible to receive dividends electronically. The required forms are available on the company and Registrar and Transfer Agent (Adroit Corporate Services) websites. This is a standard compliance measure.
Specimen of letter sent to shareholders whose shares are liable to be transferred to IEPF
Others (Uncategorized) · 25 Jun 2026, 11:12 pm
3B BlackBio Notifies Shareholders of Impending Share Transfer to IEPF 3B BlackBio Dx has issued notices, dated 25-Jun'26, to shareholders regarding the mandatory transfer of equity shares to the Investor Education and Protection Fund (IEPF). This action applies to shares where dividends have remained unpaid or unclaimed for seven consecutive years, starting from FY 2018-19. Shareholders must submit valid claims for unpaid dividends by 02-Oct'26 to prevent the transfer. Post-deadline, all affected shares and associated unclaimed dividends will be moved to the IEPF authority's demat account, with claims then needing to follow IEPF procedures.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhirendra Dubey
Acquisition/ Disposal of Shares · 25 Jun 2026, 7:20 pm
3B BlackBio Dx: Promoter Dhirendra Dubey Acquires Additional Shares Promoter Dhirendra Dubey acquired 1,000 equity shares of 3B BlackBio Dx (BSE: 532067) via an open market transaction on 24-Jun-26. This purchase increased his total shareholding from 7,24,098 shares (8.44%) to 7,25,098 shares, representing 8.45% of the company's total voting capital. The transaction was disclosed under SEBI's takeover regulations. The company's equity share capital remains at Rs 8,58,26,700, consisting of 85,82,670 equity shares of Rs 10 each.
Disclosure under Regulation 29 (2) of SEBI (SAST) Regulations, 2011
Others (Uncategorized) · 25 Jun 2026, 6:10 pm
3B BlackBio Dx Promoter Dhirendra Dubey Increases Stake Promoter Dhirendra Dubey acquired 1,000 equity shares of 3B BlackBio Dx Ltd. via an open market transaction on 24-Jun-26. Following the acquisition, his shareholding increased from 7,24,098 shares (8.44%) to 7,25,098 shares, representing 8.45% of the total voting capital. The company's total equity share capital remains at Rs 8,58,26,700, consisting of 85,82,670 equity shares. This disclosure was made under SEBI's SAST Regulations, 2011.
Transcript of Analysts/Investors Call pertaining to the Financial Results for the quarter and Financial Year ended March 31, 2026
Transcript · 04 Jun 2026, 12:02 am
3B BlackBio Dx Guides for 15-20% Growth in FY27, Coris Nears Break-Even 3B BlackBio Dx reported consolidated FY26 revenue of ₹142 cr and PAT of ₹60 cr. Management guides for 15-20% revenue growth in FY27, driven by international expansion and stable domestic demand, while maintaining a similar margin profile. The Indian molecular diagnostics business grew 10% to ₹86.47 cr. Acquired entity Coris BioConcept, which contributed ₹35.91 cr over seven months, is expected to be slightly EBITDA positive in FY27. The company is also pursuing US FDA approval for its AMR products to access the larger US market.
Audio Recording of Analysts/Investors Call pertaining to the Audited Financial Results for the quarter and financial year ended March 31, 2026
Audio / Video · 01 Jun 2026, 11:55 pm
3B BlackBio Dx Ltd: Q4 FY26 Earnings Call Recording Published 3B BlackBio Dx Ltd. has uploaded the audio recording of its analyst and investor call held to discuss the audited financial results for the quarter and financial year ended Mar 31, '26. The company, formerly Kilpest India Ltd., provided the update in a regulatory filing dated Jun 01, '26. The recording is now accessible on the company's website, providing stakeholders with direct insights from management regarding the period's financial performance and outlook.